KPC(SH:600422) KAIYUAN SECURITIES·2025-03-12 09:10Investment Rating - The investment rating for Kunming Pharmaceutical Group is "Buy" (maintained) [1] Core Views - The company is optimizing its layout in the Sanqi industry, with a focus on "innovation + international expansion" to empower future growth [1] - In 2024, the company achieved a revenue of 8.401 billion yuan, with a year-on-year growth of 9.07% before restatement and a slight decline of 0.34% after restatement [5] - The acquisition of a 51% stake in China Resources Shenghuo is a key move to resolve competition issues and optimize the Sanqi business chain [5] - The company is optimistic about the development of the silver-haired health industry and has raised profit forecasts for 2025-2027 [5] Financial Summary - Revenue for 2024 is reported at 84.01 billion yuan, with a net profit of 6.48 billion yuan, reflecting a year-on-year increase of 45.74% before restatement and 19.86% after restatement [5] - The company expects net profits for 2025, 2026, and 2027 to be 7.45 billion yuan, 9.09 billion yuan, and 11.12 billion yuan respectively, with corresponding EPS of 0.98 yuan, 1.20 yuan, and 1.47 yuan [5] - The current price-to-earnings ratio (P/E) is projected to be 18.1, 14.8, and 12.1 for the years 2025, 2026, and 2027 respectively [5] Business Segments - In 2024, the revenue from oral medications was 3.693 billion yuan (up 1.18%), while injection revenue was 539 million yuan (down 49.09%) [6] - The cardiovascular segment generated 2.195 billion yuan (down 17.45%), while the gynecology segment saw revenue of 401 million yuan (up 15.67%) [6] Innovation and Internationalization - The company invested 143 million yuan in R&D in 2024, establishing an innovative pipeline covering key areas in elderly health and chronic diseases [7] - The company has made significant strides in internationalization, with its self-developed products receiving international procurement certification [7]